



EUROPEAN
SOCIETY OF
CARDIOLOGY®

European Heart Journal

Volume 36 No. 19 May 2015

ISSUE @ A GLANCE



Prevention in high-risk patients: a long-term commitment

T.F. Lüscher

1137

CardioPulse

Calls for a higher level of professionalism in biomedical research

B. Shurlock

1140

Cleveland Clinic Abu Dhabi

T. Bartel, R. Nair, J. Bonatti, and T. Mihaljevic

1141

SHaRe: advancing the goal of effective treatment for cardiomyopathy

J.C. Fox

1142

People's corner: Mark E. Anderson MD PhD

Mark E. Anderson MD newly appointed William Osler Professor of Medicine, Director, Department of Medicine, Johns Hopkins University School of Medicine and Physician-in-Chief of the Johns Hopkins Hospital

1143

'Applied cardiology': key words of the 2014–2017 National Programme of the Romanian Society of Cardiology

G. Tatu-Chițoiu and A.O. Petriș

1144

Nitric oxide inhalation for myocardial infarction patients

A. Tofield

1145

EDITORIALS

Sweetless'n low LDL-C targets for PCSK9 treatment

B. Gencer and F. Mach

1146

Does using HbA1c inform diagnosis of diabetes in patients with coronary artery disease?

E. Standl

1149

'tis bitter cold and I am sick at heart': establishing the relationship between outdoor temperature, blood pressure, and cardiovascular mortality

R.M. Bruno and S. Taddei

1152

The role of national registries

J.G. Jollis

1155

CURRENT OPINION

What is good for the circulation also lessens cancer risk

L.H. Opie and G.D. Lopaschuk

1157

CLINICAL RESEARCH

Acute coronary syndrome

Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective

T. Jernberg, P. Hasvold, M. Henriksson, H. Hjelm, M. Thuresson, and M. Janzon

1163

Disease management

Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV—a survey from the European Society of Cardiology

V. Gyberg, D. De Bacquer, K. Kotseva, G. De Backer, O. Schnell, J. Sundvall, J. Tuomilehto, D. Wood, and L. Rydén, on behalf of EUROASPIRE IV Investigators

1171

Prevention and epidemiology

Outdoor temperature, blood pressure, and cardiovascular disease mortality among 23 000 individuals with diagnosed cardiovascular diseases from China

L. Yang, L. Li, S. Lewington, Y. Guo, P. Sherliker, Z. Bian, R. Collins, R. Peto, Y. Liu, R. Yang, Y. Zhang, G. Li, S. Liu, and Z. Chen, On Behalf of the China Kadoorie Biobank Study Collaboration

1178

Coronary artery disease

 **Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial**

C.P. Cannon, B. Cariou, D. Blom, J.M. McKenney, C. Lorenzato, R. Pordy, U. Chaudhari, and H.M. Colhoun, for the ODYSSEY COMBO II Investigators

1186

CARDIOVASCULAR FLASHLIGHTS

The world's longest follow-up after percutaneous coronary intervention, 37 years and still going strong

B. Meier

1154

Thrombus formation on the Amplatzer device: a need for critical attitude in percutaneous patent ovale closure decision-making

T. Ciurus, K. Piestrzeniewicz, M. Maciejewski, K. Łuczak, P. Jakubowski, and J. Drożdż

1195

 **Open Access Paper**

 For the podcast associated with this article, please visit <http://eurheartj.oxfordjournals.org/podcast>



Visit EHJ's mobile site
<http://m.eurheartj.oxfordjournals.org/>



www.eurheartj.org